文献速递血液净化与透析肾移植

血液透析与肾移植患者对SARS-CoV-2 mRNA疫苗的体液应答

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
PubMed 文献 · J Am Soc Nephrol · 2021-06-16

该研究评估了78例血液透析患者、74例肾移植受者和7例健康对照接种BNT162b2 mRNA疫苗后的早期血清学应答。结果显示对照组抗体在第36天达峰值,透析患者抗体滴度较低且第58天达峰,仅3例移植受者在第36天出现阳性抗体水平。

要点

  • 肾移植受者接种后体液应答受免疫抑制剂强烈抑制。
  • 血液透析患者抗体滴度低于健康对照,且达峰延迟。
  • 透析患者中年龄<75岁、血清白蛋白和Kt/V与抗体应答正相关。

核心结论

  • 肾移植受者的疫苗接种后体液应答被免疫抑制剂强烈抑制。
  • 血液透析患者的体液应答因尿毒症状态而降低。

研究设计与样本

  • 研究纳入78例血液透析患者、74例肾移植受者和7例健康对照,接种Pfizer/BioNTech(BNT162b2)mRNA疫苗。
  • 在第0、14、28、36和58天测量抗SARS-CoV-2抗体滴度,并记录包括乙肝疫苗接种应答在内的临床参数。

主要发现

  • 对照组在第14天检测到阳性抗体水平(>13 AU/ml),第36天达峰值1082 AU/ml(IQR 735.0-1662.0)。
  • 血液透析患者抗体滴度较低,第58天达峰值276 AU/ml(IQR 83.4-526.0)。
  • 仅3例肾移植受者在第36天检测到阳性抗体水平。
  • 血液透析患者中,年龄<75岁者抗体应答高于>75岁者,血清白蛋白和Kt/V与血清学应答正相关(P<0.04和P<0.0)。
  • 乙肝疫苗无应答者的抗SARS-CoV-2抗体滴度最低。

临床怎么用

  • 肾移植受者和血液透析患者接种mRNA疫苗后应监测抗体应答。
  • 透析患者中年龄<75岁、较高血清白蛋白和Kt/V者抗体应答较好。
  • 乙肝疫苗无应答的透析患者可能对SARS-CoV-2疫苗应答也较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kidney transplant recipients and patients receiving hemodialysis are immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded from clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers and rates of seroconversion after vaccination are lower among patients with CKD and those taking immunosuppressants compared with controls. Data are lacking regarding their humoral response to vaccination to prevent COVID-19. METHODS: This investigation of early serological response after COVID-19 vaccination with the Pfizer/BioNTech (BNT162b2) mRNA vaccine included 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and seven healthy controls. We recorded data from the medical file for various clinical parameters, including response to hepatitis B vaccination, and measured antibody titers against SARS-CoV-2 at 0, 14, 28, 36, and 58 days after the first injection. RESULTS: In controls, we detected antibodies at a positive level (>13 arbitrary units per ml; AU/ml) at day 14 postinjection, which increased progressively to peak at day 36 (1082 AU/ml; interquartile range [IQR], 735.0-1662.0). Patients undergoing hemodialysis had lower titers that peaked at day 58 (276 AU/ml; IQR, 83.4-526.0). We detected a positive antibody level in only three transplant recipients at day 36. In patients on hemodialysis, those aged <75 years had a higher antibody response versus those aged >75 years, and serum albumin and Kt/V were positively correlated with serological response (P<0.04 and P<0.0, respectively); nonresponders to HBV vaccine had the lowest anti-SARS-CoV-2 antibody titers. CONCLUSIONS: Our results suggest that the postvaccination humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, and is reduced by the uremic condition in patients undergoing hemodialysis.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Danthu C, Hantz S, Dahlem A, et al. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. J Am Soc Nephrol. 2021. PMID: 34135083. doi:10.1681/ASN.2021040490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。